By Mill Chart
Last update: Feb 14, 2024
Our stock screener has singled out NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as an attractive growth opportunity. NYSE:NVO is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NYSE:NVO has earned a 8 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NYSE:NVO, the assigned 5 reflects its valuation:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 8 out of 10:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Check the latest full fundamental report of NVO for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (4/29/2024, 6:19:07 PM)
After market: 127.5 +0.62 (+0.49%)126.88
+0.03 (+0.02%)
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.
After a bounceback week for stocks, a Fed meeting, jobs report, and a busy week of corporate earnings are set to greet investors.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.
Lilly recently announced news that could solve a big problem.
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?